JP2016524611A5 - - Google Patents

Download PDF

Info

Publication number
JP2016524611A5
JP2016524611A5 JP2016515080A JP2016515080A JP2016524611A5 JP 2016524611 A5 JP2016524611 A5 JP 2016524611A5 JP 2016515080 A JP2016515080 A JP 2016515080A JP 2016515080 A JP2016515080 A JP 2016515080A JP 2016524611 A5 JP2016524611 A5 JP 2016524611A5
Authority
JP
Japan
Prior art keywords
level
cancer
vegf
fgf2
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016515080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/039129 external-priority patent/WO2014190147A2/en
Publication of JP2016524611A publication Critical patent/JP2016524611A/ja
Publication of JP2016524611A5 publication Critical patent/JP2016524611A5/ja
Pending legal-status Critical Current

Links

JP2016515080A 2013-05-23 2014-05-22 がんを治療する方法 Pending JP2016524611A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361826975P 2013-05-23 2013-05-23
US61/826,975 2013-05-23
US201461936471P 2014-02-06 2014-02-06
US61/936,471 2014-02-06
US201461974279P 2014-04-02 2014-04-02
US61/974,279 2014-04-02
PCT/US2014/039129 WO2014190147A2 (en) 2013-05-23 2014-05-22 Methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018169261A Division JP2019023193A (ja) 2013-05-23 2018-09-11 がんを治療する方法

Publications (2)

Publication Number Publication Date
JP2016524611A JP2016524611A (ja) 2016-08-18
JP2016524611A5 true JP2016524611A5 (https=) 2017-07-13

Family

ID=51934346

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016515080A Pending JP2016524611A (ja) 2013-05-23 2014-05-22 がんを治療する方法
JP2018169261A Pending JP2019023193A (ja) 2013-05-23 2018-09-11 がんを治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018169261A Pending JP2019023193A (ja) 2013-05-23 2018-09-11 がんを治療する方法

Country Status (14)

Country Link
US (1) US9775881B2 (https=)
EP (2) EP3252171B8 (https=)
JP (2) JP2016524611A (https=)
KR (1) KR20160013092A (https=)
CN (1) CN105307669A (https=)
AU (1) AU2014268519A1 (https=)
BR (1) BR112015029145A2 (https=)
CA (1) CA2909689A1 (https=)
HK (1) HK1219513A1 (https=)
MX (1) MX2015015426A (https=)
RU (1) RU2015154985A (https=)
SG (2) SG10201703977UA (https=)
WO (1) WO2014190147A2 (https=)
ZA (1) ZA201507762B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201703977UA (en) * 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
US10954282B2 (en) 2014-12-09 2021-03-23 Wentao Zhang NBP158 and uses thereof
GB201609402D0 (en) * 2016-05-27 2016-07-13 Cancer Res Inst Royal Materials and methods for treating cancer
JP2021518532A (ja) * 2018-03-16 2021-08-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー がんにおける治療薬に対する応答の分析
US20250304694A1 (en) * 2022-06-29 2025-10-02 Korea University Research And Business Foundation Glycosylated fc variants of which binding affinity for human fcgrs is removed
WO2025221718A1 (en) * 2024-04-15 2025-10-23 Arizona Board Of Regents On Behalf Of Arizona State University Repurposing fda approved therapeutics

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001075166A2 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
DK1638941T3 (da) 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP2008530122A (ja) * 2005-02-14 2008-08-07 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド Ｃ１０シクロプロピルエステル置換タキサン組成物
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP2009514879A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
AR063975A1 (es) * 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
KR101910779B1 (ko) * 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
US20120308562A1 (en) * 2011-06-03 2012-12-06 Derynck Mika K Methods of treating mesothelioma with a pi3k inhibitor compound
SG10201703977UA (en) * 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer

Similar Documents

Publication Publication Date Title
Kienast et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy
Hidalgo et al. First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors
Clarke et al. Understanding and targeting resistance to anti-angiogenic therapies
Lazăr et al. New advances in targeted gastric cancer treatment
Deng et al. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Chan et al. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Rougier et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Limaverde-Sousa et al. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents
Aprile et al. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use
Cheng et al. Molecularly targeted drugs for metastatic colorectal cancer
JP2016524611A5 (https=)
Li et al. Current molecular targeted therapy in advanced gastric cancer: A comprehensive review of therapeutic mechanism, clinical trials, and practical application
Rivera et al. Cetuximab, its clinical use and future perspectives
Eroglu et al. Targeting angiopoietin-2 signaling in cancer therapy
Jitawatanarat et al. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib
Vergote et al. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
Balsano et al. State of the art for metastatic pancreatic cancer treatment: Where are we now?
Lee et al. Options for second-line treatment in metastatic colorectal cancer
Vermorken et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
Seystahl et al. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Lee et al. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Wang et al. Advances in drugs targeting lymphangiogenesis for preventing tumor progression and metastasis
Mok et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non‐squamous non‐small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial
Li et al. Combination of anti-EGFR and anti-VEGF drugs for the treatment of previously treated metastatic colorectal cancer: a case report and literature review
Koukourakis et al. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer